The anti-CD20 monoclonal antibody (mAb) rituximab was administered in 15 patients with renal cell carcinoma and 6 with melanoma before treatment with low doses of IL-2 in a clinical trial, without conferring any beneficial effects.109. This evidence concerns the gene IL2 and melanoma.